Kissei Pharmaceutical Co., Ltd
https://www.kissei.co.jp/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kissei Pharmaceutical Co., Ltd
Lilly Adds To Radiopharma Arsenal With Option To Buy Radionetics
Lilly paid $140m up front for an option to acquire Radionetics for $1bn within an undisclosed timeframe. The private firm is developing small molecule GPCR-targeted radiopharmaceuticals.
Asia Deal Watch: Chugai Extends Relationship With Helsinn
Plus deals involving Kissei/JWP, Shionogi/Cilcare, Takeda/Torrent, Genome & Co./Debiopharm, Kaken/J&J, CStone/Ewopharma, MediLink/BioNTech and more.
Ipsen Gets Ahead Of The Qirv in Cholangitis
Iqirvo gains accelerated approval, but Gilead’s seladelpar is probably only two months behind.
Ipsen Dealmaking Heats Up With Marengo Cold Tumor Collaboration
The France-based mid-sized drugmaker has solidified its pipeline through several external pacts in the past few years and its dealmaking is showing no signs of slowing down.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Kissei Yakuhin Kogyo Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice